Theravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of “Hold” from Analysts
Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given an average rating of “Hold” by the eleven research firms that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $42.17.
A number of brokerages have commented on TBPH. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, August 16th. Evercore ISI began coverage on shares of Theravance Biopharma in a research report on Wednesday, August 16th. They set an “outperform” rating and a $45.00 price target on the stock. BidaskClub cut shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. ValuEngine cut shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th.
TRADEMARK VIOLATION WARNING: “Theravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of “Hold” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/12/theravance-biopharma-inc-tbph-receives-consensus-recommendation-of-hold-from-analysts.html.
Shares of Theravance Biopharma (NASDAQ TBPH) opened at 32.26 on Tuesday. The firm’s 50-day moving average is $29.84 and its 200-day moving average is $35.28. The company’s market capitalization is $1.74 billion. Theravance Biopharma has a 12-month low of $23.15 and a 12-month high of $43.44.
In other news, EVP Bradford J. Shafer sold 14,670 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total value of $451,395.90. Following the transaction, the executive vice president now owns 134,327 shares in the company, valued at $4,133,241.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Henrietta Fore bought 6,000 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was purchased at an average price of $23.99 per share, for a total transaction of $143,940.00. Following the acquisition, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $575,760. The disclosure for this purchase can be found here. Insiders bought 20,000 shares of company stock worth $494,300 in the last 90 days. Company insiders own 6.10% of the company’s stock.
Several institutional investors have recently modified their holdings of TBPH. Teachers Advisors LLC grew its holdings in shares of Theravance Biopharma by 19.2% in the fourth quarter. Teachers Advisors LLC now owns 69,563 shares of the biopharmaceutical company’s stock worth $2,218,000 after purchasing an additional 11,201 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Theravance Biopharma by 10.6% in the first quarter. Wells Fargo & Company MN now owns 32,270 shares of the biopharmaceutical company’s stock valued at $1,188,000 after acquiring an additional 3,100 shares in the last quarter. American Century Companies Inc. bought a new stake in Theravance Biopharma in the first quarter valued at $1,132,000. Bank of New York Mellon Corp boosted its holdings in Theravance Biopharma by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 206,023 shares of the biopharmaceutical company’s stock valued at $7,586,000 after acquiring an additional 5,188 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in Theravance Biopharma by 1.7% in the first quarter. Swiss National Bank now owns 64,442 shares of the biopharmaceutical company’s stock valued at $2,373,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 84.54% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.